Skip to main content
Top
Published in: BMC Immunology 1/2010

Open Access 01-12-2010 | Methodology article

Novel Method of Monitoring Trace Cytokines and Activated STAT Molecules in the Paws of Arthritic Mice using Multiplex Bead Technology

Authors: Lily D Lu, Kristine L Stump, Matthew M Seavey

Published in: BMC Immunology | Issue 1/2010

Login to get access

Abstract

Background

The use of mouse models to study human disease provides useful data that can provide support for research projects or an existing drug discovery program. How well a model recapitulates the human condition and the ease and reproducibility of data collected will determine how much confidence a scientist can place on results obtained. Designing new treatments for rheumatic diseases, such as rheumatoid arthritis (RA), requires complex immunocompetent models that depend on intricate cytokine networks. Using local cytokines, signal transduction and transcription factor molecules as potential biomarkers to monitor disease and treatment efficacy is the best method to follow the progression of tissue damage and repair when testing an unknown compound or biologic. Described here in this report, a novel method for the non-enzymatic extraction and measurement of cytokines and signal transducers and activators of transcription (STAT) molecules using Luminex® bead array technology in two different mouse models for human RA - collagen antibody-dependent arthritis (CAIA) and collagen-induced arthritis (CIA).

Results

Dynamic expression of several pro-inflammatory cytokines responsible for promoting disease augmentation overtime were monitored, such as IL-1β, TNFα, IL-6 and IL-12, locally in the paws of affected animals directly ex vivo. Local cytokine responses could be matched with serum cytokine levels and joint pathology results. In addition, STAT1, 3, and 5a/b activation status could be monitored with confidence using specifically formulated extraction buffer that protected the phosphorylation site. STAT3 activation followed paw swelling and cytokine levels in both models and correlates of disease could be ablated upon treatment with dexamethasone. Here reported a novel method of extracting joint fluid from the paws of inflamed mice coupled with powerful multiplex bead technology allowing us to measure cytokine responses, pharmacodynamic markers such as STATs and pharmacokinetic analysis of dosed agent all from the same sample directly ex vivo.

Conclusions

This method is powerful in that it is applicable to multiple autoimmunity model types, streamlines ex vivo readouts in a high-throughput manner, and allows multiplexing providing the investigator with an array of options and possible analytes when developing preclinical animal models to support drug discovery efforts in the search for new treatments for rheumatic diseases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010, 233: 301-12. 10.1111/j.0105-2896.2009.00857.x.CrossRefPubMed Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010, 233: 301-12. 10.1111/j.0105-2896.2009.00857.x.CrossRefPubMed
2.
3.
go back to reference David AHK, Brand D, Rosloniec Edward F: The Mouse Model of Collagen-Induced Arthritis. Methods in Molecular Medicine. Edited by: Perl A. 2004, Totowa, NJ: Humana Press Inc, 102: 295-312. David AHK, Brand D, Rosloniec Edward F: The Mouse Model of Collagen-Induced Arthritis. Methods in Molecular Medicine. Edited by: Perl A. 2004, Totowa, NJ: Humana Press Inc, 102: 295-312.
4.
go back to reference Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 992-9. 10.1136/ard.2006.060822.PubMedCentralCrossRefPubMed Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 992-9. 10.1136/ard.2006.060822.PubMedCentralCrossRefPubMed
5.
go back to reference Sweeney SE, Firestein GS: Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004, 36: 372-8. 10.1016/S1357-2725(03)00259-0.CrossRefPubMed Sweeney SE, Firestein GS: Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004, 36: 372-8. 10.1016/S1357-2725(03)00259-0.CrossRefPubMed
7.
go back to reference Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006, 65: 149-56. 10.1136/ard.2005.037929.PubMedCentralCrossRefPubMed Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006, 65: 149-56. 10.1136/ard.2005.037929.PubMedCentralCrossRefPubMed
8.
go back to reference Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006, 65: 1558-64. 10.1136/ard.2005.050385.PubMedCentralCrossRefPubMed Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006, 65: 1558-64. 10.1136/ard.2005.050385.PubMedCentralCrossRefPubMed
9.
go back to reference aAL Verdenius HHW: A quantitative study of decalcification methods in histology. J Clin Pathol. 1958, 11: 229-236. 10.1136/jcp.11.3.229.CrossRef aAL Verdenius HHW: A quantitative study of decalcification methods in histology. J Clin Pathol. 1958, 11: 229-236. 10.1136/jcp.11.3.229.CrossRef
10.
go back to reference Eggert FM, Germain JP: Rapid demineralization in acidic buffers. Histochemistry. 1979, 59: 215-24. 10.1007/BF00495669.CrossRefPubMed Eggert FM, Germain JP: Rapid demineralization in acidic buffers. Histochemistry. 1979, 59: 215-24. 10.1007/BF00495669.CrossRefPubMed
11.
go back to reference Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al.,: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009, 15: 781-7. 10.1038/nm.1978.CrossRefPubMed Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al.,: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009, 15: 781-7. 10.1038/nm.1978.CrossRefPubMed
12.
go back to reference Chia WT, LT Yeh, Chen YW, HS Lee, Chang DM, Sytwu HK: IL-1beta in irrigation fluid and mRNA expression in synovial tissue of the knee joint as therapeutic markers of inflammation in collagen antibody-induced arthritis. Dis Markers. 2009, 26: 1-7.PubMedCentralCrossRefPubMed Chia WT, LT Yeh, Chen YW, HS Lee, Chang DM, Sytwu HK: IL-1beta in irrigation fluid and mRNA expression in synovial tissue of the knee joint as therapeutic markers of inflammation in collagen antibody-induced arthritis. Dis Markers. 2009, 26: 1-7.PubMedCentralCrossRefPubMed
13.
go back to reference Chia WT, Chen YW, Cheng LY, Lee HS, Chang DM, Sytwu HK: MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J Formos Med Assoc. 2008, 107: 245-52. 10.1016/S0929-6646(08)60143-6.CrossRefPubMed Chia WT, Chen YW, Cheng LY, Lee HS, Chang DM, Sytwu HK: MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J Formos Med Assoc. 2008, 107: 245-52. 10.1016/S0929-6646(08)60143-6.CrossRefPubMed
14.
go back to reference West K: CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs. 2009, 10: 491-504.PubMed West K: CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs. 2009, 10: 491-504.PubMed
15.
go back to reference Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH: Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010, 69: 413-6. 10.1136/ard.2009.108159.CrossRefPubMed Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH: Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010, 69: 413-6. 10.1136/ard.2009.108159.CrossRefPubMed
16.
go back to reference Billich A: Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs. 2007, 10: 53-9.PubMed Billich A: Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs. 2007, 10: 53-9.PubMed
17.
go back to reference McCluggage LK, Scholtz JM: Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2010, 44: 135-44. 10.1345/aph.1M227.CrossRefPubMed McCluggage LK, Scholtz JM: Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2010, 44: 135-44. 10.1345/aph.1M227.CrossRefPubMed
18.
go back to reference Nandakumar KS, Holmdahl R: Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods. 2005, 304: 126-36. 10.1016/j.jim.2005.06.017.CrossRefPubMed Nandakumar KS, Holmdahl R: Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods. 2005, 304: 126-36. 10.1016/j.jim.2005.06.017.CrossRefPubMed
19.
go back to reference Geyer M, Muller-Ladner U: Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol. 2010, 22: 246-51. 10.1097/BOR.0b013e3283373fa0.CrossRefPubMed Geyer M, Muller-Ladner U: Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol. 2010, 22: 246-51. 10.1097/BOR.0b013e3283373fa0.CrossRefPubMed
20.
go back to reference van Vollenhoven RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009, 5: 531-41. 10.1038/nrrheum.2009.182.CrossRefPubMed van Vollenhoven RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009, 5: 531-41. 10.1038/nrrheum.2009.182.CrossRefPubMed
21.
go back to reference Fitzgerald LAJON Katherine, Gearing Andy, Callard Robin: The Cytokine Facts Book. 2001, San Diego, California, USA: Academic Press, 2 Fitzgerald LAJON Katherine, Gearing Andy, Callard Robin: The Cytokine Facts Book. 2001, San Diego, California, USA: Academic Press, 2
22.
go back to reference Gorak PM, Engwerda CR, Kaye PM: Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998, 28: 687-95. 10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N.CrossRefPubMed Gorak PM, Engwerda CR, Kaye PM: Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998, 28: 687-95. 10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N.CrossRefPubMed
23.
go back to reference D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, et al.,: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992, 176: 1387-98. 10.1084/jem.176.5.1387.CrossRefPubMed D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, et al.,: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992, 176: 1387-98. 10.1084/jem.176.5.1387.CrossRefPubMed
24.
go back to reference Hakonarson H, Maskeri N, Carter C, Grunstein MM: Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest. 1999, 103: 1077-87. 10.1172/JCI5809.PubMedCentralCrossRefPubMed Hakonarson H, Maskeri N, Carter C, Grunstein MM: Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest. 1999, 103: 1077-87. 10.1172/JCI5809.PubMedCentralCrossRefPubMed
25.
go back to reference DeForge LE, Remick DG: Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun. 1991, 174: 18-24. 10.1016/0006-291X(91)90478-P.CrossRefPubMed DeForge LE, Remick DG: Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun. 1991, 174: 18-24. 10.1016/0006-291X(91)90478-P.CrossRefPubMed
26.
go back to reference Cho YG, Cho ML, Min SY, Kim HY: Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007, 7: 65-70. 10.1016/j.autrev.2007.08.001.CrossRefPubMed Cho YG, Cho ML, Min SY, Kim HY: Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007, 7: 65-70. 10.1016/j.autrev.2007.08.001.CrossRefPubMed
27.
go back to reference Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol. 1993, 11: 165-90. 10.1146/annurev.iy.11.040193.001121.CrossRefPubMed Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol. 1993, 11: 165-90. 10.1146/annurev.iy.11.040193.001121.CrossRefPubMed
28.
go back to reference Kishimoto T, Akira S, Taga T: Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992, 258: 593-7. 10.1126/science.1411569.CrossRefPubMed Kishimoto T, Akira S, Taga T: Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992, 258: 593-7. 10.1126/science.1411569.CrossRefPubMed
29.
go back to reference Zvonic S, Baugh JE, Arbour-Reily P, Mynatt RL, Stephens JM: Cross-talk among gp130 cytokines in adipocytes. J Biol Chem. 2005, 280: 33856-63. 10.1074/jbc.M508020200.CrossRefPubMed Zvonic S, Baugh JE, Arbour-Reily P, Mynatt RL, Stephens JM: Cross-talk among gp130 cytokines in adipocytes. J Biol Chem. 2005, 280: 33856-63. 10.1074/jbc.M508020200.CrossRefPubMed
30.
go back to reference Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006, 92: 1-69. full_text.CrossRefPubMed Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006, 92: 1-69. full_text.CrossRefPubMed
32.
go back to reference Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R: NZB/NZW mice as a model of systemic lupus erythematosus. Jama. 1966, 195: 285-9. 10.1001/jama.195.4.285.CrossRefPubMed Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R: NZB/NZW mice as a model of systemic lupus erythematosus. Jama. 1966, 195: 285-9. 10.1001/jama.195.4.285.CrossRefPubMed
33.
go back to reference MAM Philip Cohen: Animal Models for SLE. Current Protocols in Immunology. 2002, Hoboken, NJ: John Wiley & Sons, Inc, 15: 15.20.1-15.20.22. MAM Philip Cohen: Animal Models for SLE. Current Protocols in Immunology. 2002, Hoboken, NJ: John Wiley & Sons, Inc, 15: 15.20.1-15.20.22.
34.
go back to reference Campbell IK, Bendele A, Smith DA, Hamilton JA: Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis. 1997, 56: 364-8. 10.1136/ard.56.6.364.PubMedCentralCrossRefPubMed Campbell IK, Bendele A, Smith DA, Hamilton JA: Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis. 1997, 56: 364-8. 10.1136/ard.56.6.364.PubMedCentralCrossRefPubMed
35.
go back to reference Alexopoulou L, Pasparakis M, Kollias G: A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol. 1997, 27: 2588-92. 10.1002/eji.1830271018.CrossRefPubMed Alexopoulou L, Pasparakis M, Kollias G: A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol. 1997, 27: 2588-92. 10.1002/eji.1830271018.CrossRefPubMed
36.
go back to reference Shiao RT, Miglietta L, Khera SY, Wolfson A, Freter CE: Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leuk Lymphoma. 1995, 17: 485-94. 10.3109/10428199509056862.CrossRefPubMed Shiao RT, Miglietta L, Khera SY, Wolfson A, Freter CE: Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leuk Lymphoma. 1995, 17: 485-94. 10.3109/10428199509056862.CrossRefPubMed
37.
go back to reference Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al.,: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004, 10: 48-54. 10.1038/nm976.CrossRefPubMed Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al.,: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004, 10: 48-54. 10.1038/nm976.CrossRefPubMed
38.
go back to reference H Yu, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809. 10.1038/nrc2734.CrossRef H Yu, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809. 10.1038/nrc2734.CrossRef
39.
40.
go back to reference Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009, 324: 1713-6. 10.1126/science.1171721.PubMedCentralCrossRefPubMed Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009, 324: 1713-6. 10.1126/science.1171721.PubMedCentralCrossRefPubMed
41.
go back to reference Costantino L, Barlocco D: STAT 3 as a target for cancer drug discovery. Curr Med Chem. 2008, 15: 834-43. 10.2174/092986708783955464.CrossRefPubMed Costantino L, Barlocco D: STAT 3 as a target for cancer drug discovery. Curr Med Chem. 2008, 15: 834-43. 10.2174/092986708783955464.CrossRefPubMed
42.
go back to reference Kikkawa E, Yamashita M, Kimura M, Omori M, Sugaya K, Shimizu C, Katsumoto T, Ikekita M, Taniguchi M, Nakayama T: T(h)1/T(h)2 cell differentiation of developing CD4 single-positive thymocytes. Int Immunol. 2002, 14: 943-51. 10.1093/intimm/dxf057.CrossRefPubMed Kikkawa E, Yamashita M, Kimura M, Omori M, Sugaya K, Shimizu C, Katsumoto T, Ikekita M, Taniguchi M, Nakayama T: T(h)1/T(h)2 cell differentiation of developing CD4 single-positive thymocytes. Int Immunol. 2002, 14: 943-51. 10.1093/intimm/dxf057.CrossRefPubMed
43.
go back to reference Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, et al.,: Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001, 292: 1907-10. 10.1126/science.1059835.CrossRefPubMed Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, et al.,: Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001, 292: 1907-10. 10.1126/science.1059835.CrossRefPubMed
44.
go back to reference Shi M, Lin TH, Appell KC, Berg LJ: Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity. 2008, 28: 763-73. 10.1016/j.immuni.2008.04.016.PubMedCentralCrossRefPubMed Shi M, Lin TH, Appell KC, Berg LJ: Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity. 2008, 28: 763-73. 10.1016/j.immuni.2008.04.016.PubMedCentralCrossRefPubMed
45.
go back to reference Antonelli A, Bianchi M, Crinelli R, Gentilini L, Magnani M: Modulation of ICAM-1 expression in ECV304 cells by macrophage-released cytokines. Blood Cells Mol Dis. 2001, 27: 978-91. 10.1006/bcmd.2001.0470.CrossRefPubMed Antonelli A, Bianchi M, Crinelli R, Gentilini L, Magnani M: Modulation of ICAM-1 expression in ECV304 cells by macrophage-released cytokines. Blood Cells Mol Dis. 2001, 27: 978-91. 10.1006/bcmd.2001.0470.CrossRefPubMed
46.
go back to reference Buttgereit F, Straub RH, Wehling M, Burmester GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004, 50: 3408-17. 10.1002/art.20583.CrossRefPubMed Buttgereit F, Straub RH, Wehling M, Burmester GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004, 50: 3408-17. 10.1002/art.20583.CrossRefPubMed
47.
go back to reference Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, et al.,: Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010, 10: 62-7. 10.3816/CLML.2010.n.007.CrossRefPubMed Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, et al.,: Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010, 10: 62-7. 10.3816/CLML.2010.n.007.CrossRefPubMed
48.
go back to reference Spies CM, Bijlsma JW, Burmester GR, Buttgereit F: Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010, 10: 302-7. 10.1016/j.coph.2010.02.001.CrossRefPubMed Spies CM, Bijlsma JW, Burmester GR, Buttgereit F: Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010, 10: 302-7. 10.1016/j.coph.2010.02.001.CrossRefPubMed
Metadata
Title
Novel Method of Monitoring Trace Cytokines and Activated STAT Molecules in the Paws of Arthritic Mice using Multiplex Bead Technology
Authors
Lily D Lu
Kristine L Stump
Matthew M Seavey
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2010
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-11-55

Other articles of this Issue 1/2010

BMC Immunology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.